NASDAQ:QURE

uniQure - QURE Stock Forecast, Price & News

$20.21

+0.10 (+0.50%)

(As of 10/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $19.80
▼
$20.49
50-Day Range: $16.98
▼
$25.54
52-Week Range: $12.52
▼
$36.55

Volume: 377,950 shs
Average Volume: 617,710 shs
Market Capitalization: $944.39 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $48.38

uniQure MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 139.4% Upside
$48.38 Price Target
Short Interest: Bearish
7.12% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$868,032 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.61) to ($1.14) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

859th out of 1,075 stocks

Pharmaceutical Preparations Industry

416th out of 537 stocks

3.4

Analyst's Opinion

Consensus Rating
uniQure has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $48.38, uniQure has a forecasted upside of 139.4% from its current price of $20.21.
Amount of Analyst Coverage
uniQure has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.12% of the float of uniQure has been sold short.
Short Interest Ratio / Days to Cover
uniQure has a short interest ratio ("days to cover") of 4.2.
Change versus previous month
Short interest in uniQure has recently decreased by 1.00%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
uniQure does not currently pay a dividend.
Dividend Growth
uniQure does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for QURE.

0.0

News and Social Media Coverage

Search Interest
Only 4 people have searched for QURE on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added uniQure to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, uniQure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $868,032.00 in company stock.
Percentage Held by Insiders
Only 3.10% of the stock of uniQure is held by insiders.
Percentage Held by Institutions
86.46% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for uniQure are expected to grow in the coming year, from ($3.61) to ($1.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of uniQure is -8.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of uniQure is -8.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
uniQure has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About uniQure (NASDAQ:QURE) Stock

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Receive QURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

QURE Stock News Headlines

February 7, 2022 | globenewswire.com

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's Disease - GlobeNewswire

February 7, 2022 | finance.yahoo.com

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease

February 5, 2022 | washingtonpost.com

With CRISPR gene editing, unique treatments begin to take off for rare diseases - The Washington Post

February 4, 2022 | finance.yahoo.com

Global Gene Therapy for Blood Disorders Market worth US$ 5.79 Billion by 2030 - Exclusive Report by InsightAce Analytic - Yahoo Finance

February 4, 2022 | reuters.com

Amazon has a unique inflation problem - Reuters

February 3, 2022 | washingtonpost.com

Turkey's Recep Tayyip Erdogan is the latest leader to visit Ukraine - The Washington Post

February 2, 2022 | forbes.com

Looking To Fill Unique Sports Merchandise Void, ‘Official League’ Launches Lifestyle Brand - Forbes

February 2, 2022 | bbc.com

Deliberate infections give unique Covid insight - BBC News

January 31, 2022 | pymnts.com

What Makes the UE’s Digital Markets Act Unique - pymnts.com

January 31, 2022 | patriotswire.usatoday.com

Bill Belichick has unique hiring opportunities if everyone swallows their pride - Patriots Wire

January 31, 2022 | abcnews.go.com

Review: Unique narrator propels 'What the Fireflies Knew' - ABC News

January 31, 2022 | globenewswire.com

UNIUM Produces Unique Influencer NFT in Its Marketplace - GlobeNewswire

January 28, 2022 | saintswire.usatoday.com

How Sean Payton helped save the Saints, and build a unique bond with fans - Saints Wire

January 27, 2022 | forbes.com

Small Business Owners Have A Truly Unique Roth Contribution Opportunity! - Forbes

January 27, 2022 | latimes.com

These unique creations for three films had us at hello - Los Angeles Times

January 25, 2022 | 6sqft.com

13 unique gift ideas for Valentine's Day - 6Sqft

January 25, 2022 | latimes.com

SAT making big changes: going digital, concise, unique tests - Los Angeles Times

January 24, 2022 | forbes.com

A Financial Negative Could Be A Marketing Positive As Seton Hall Showcases Its Program In A Unique Setting - Forbes

January 21, 2022 | finance.yahoo.com

Crosschq Launches Unique Platform to Source Talent with Candidate Referral Network "Crosschq Recruit" - Yahoo Finance

January 20, 2022 | globenewswire.com

Soulful Traveling Unveils Unique Adventures - GlobeNewswire

January 20, 2022 | forbes.com

Bloomberg Strategist: Bitcoin’s ‘Unique Phase’ Will Send Its Price To $100,000 In 2022—Meanwhile Ethereum, BNB, Cardano, Solana Prices Tumble - Forbes

January 20, 2022 | forbes.com

Valentine's Day Gift Guide: Unique Vow Renewal Experiences Around The World - Forbes

January 19, 2022 | forbes.com

Meet The Female Founder Of A Unique Trading Platform With A Social Spin - Forbes

January 18, 2022 | forbes.com

10 Years On: How Novikov Is Still One Of London’s Most Unique Dining Spots - Forbes

January 18, 2022 | seekingalpha.com

uniQure: Betting On Hemophilia-B Cure - Seeking Alpha

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive QURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

QURE Company Calendar

Last Earnings: 8/08/2022
Today: 10/06/2022
Next Earnings (Estimated): 10/24/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:QURE
CUSIP: N/A
CIK: 1590560
Web: www.uniqure.com
Phone: (120) 240-6000
Fax: 31-20-566-9272
Employees: 463
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $48.38
High Stock Price Forecast: $66.00
Low Stock Price Forecast: $24.00
Forecasted Upside/Downside: +139.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $329.59 million
Net Margins: -184.06%
Pretax Margin: -185.98%
Return on Equity: -20.56%
Return on Assets: -15.00%

Debt

Debt-to-Equity Ratio: 0.21
Current Ratio: 10.84
Quick Ratio: 10.78

Sales & Book Value

Annual Sales: $524 million
Price / Sales: 1.80
Cash Flow: $7.27 per share
Price / Cash Flow: 2.78
Book Value: $12.89 per share
Price / Book: 1.57

Miscellaneous

Outstanding Shares: 46,729,000
Free Float: 45,280,000
Market Cap: $944.39 million
Optionable: Optionable
Beta: 1.05

Key Executives

Mr. Matthew Craig Kapusta (Age 50)
CEO & Exec. Director
Comp: $969.95k

Mr. Christian Klemt (Age 49)
CFO, Principal Financial Officer & GM of Amsterdam Site
Comp: $505.02k

Mr. Pierre Caloz
Chief Operating Officer

Dr. Alexander E. Kuta Ph.D. (Age 62)
Exec. VP of Quality & Regulatory Affairs
Comp: $649.26k

Dr. Ricardo Dolmetsch Ph.D. (Age 53)
Pres of R&D
Comp: $795.35k

Prof. Hugo Katus
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany

Mr. David Cerveny (Age 55)
Chief Legal Officer, Gen. Counsel & Sec.

Dr. Tamara Tugal Ph.D.
MBA, Bus. Devel. Director

Ms. Erin Boyer
Chief People & Culture Office

Ms. Maria E. Cantor (Age 54)
Chief Corp. Affairs Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

QURE Stock - Frequently Asked Questions

Should I buy or sell uniQure stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QURE shares.
View QURE analyst ratings or view top-rated stocks.
What is uniQure's stock price forecast for 2022?: 7 brokers have issued 1-year target prices for uniQure's shares. Their QURE share price forecasts range from $24.00 to $66.00. On average, they predict the company's stock price to reach $48.38 in the next year. This suggests a possible upside of 139.4% from the stock's current price.
View analysts price targets for QURE or view top-rated stocks among Wall Street analysts.
How have QURE shares performed in 2022?: uniQure's stock was trading at $20.74 on January 1st, 2022. Since then, QURE shares have decreased by 2.6% and is now trading at $20.21.
View the best growth stocks for 2022 here.
When is uniQure's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, October 24th 2022.
View our QURE earnings forecast.
How were uniQure's earnings last quarter?: uniQure (NASDAQ:QURE) issued its quarterly earnings data on Monday, August, 8th. The biotechnology company reported ($0.84) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.12. The biotechnology company earned $0.50 million during the quarter, compared to the consensus estimate of $19.66 million. uniQure had a negative trailing twelve-month return on equity of 20.56% and a negative net margin of 184.06%.
What is Matthew Kapusta's approval rating as uniQure's CEO?: 8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees.

What other stocks do shareholders of uniQure own?: Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Block (SQ) and bluebird bio (BLUE).
What is uniQure's stock symbol?: uniQure trades on the NASDAQ under the ticker symbol "QURE."
How do I buy shares of uniQure?: Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is uniQure's stock price today?: One share of QURE stock can currently be purchased for approximately $20.21.
How much money does uniQure make?: uniQure (NASDAQ:QURE) has a market capitalization of $944.39 million and generates $524 million in revenue each year. The biotechnology company earns $329.59 million in net income (profit) each year or ($2.46) on an earnings per share basis.
How many employees does uniQure have?: The company employs 463 workers across the globe.
How can I contact uniQure?: uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The official website for the company is www.uniqure.com. The biotechnology company can be reached via phone at (120) 240-6000, via email at investors@uniqure, or via fax at 31-20-566-9272.

This page (NASDAQ:QURE) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

uniQure - QURE Stock Forecast, Price & News

uniQure MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month